NCOA3 impacts the pharmacodynamics of breast cancer drugs, tamoxifen and letrozole, by influencing their effectiveness through its role as a coactivator protein required for their activity. Variations in the NCOA3 gene can affect the efficacy of these drugs, which are critical in managing hormone-responsive cancers, suggesting the importance of this gene in personalized cancer treatment strategies.